Adenocarcinoma
Showing 1 - 25 of 8,125
Local and Peripheral Immune Responsive Landscape Induced by
Not yet recruiting
- Lung Adenocarcinoma
- Local Cryoablation
- (no location specified)
Oct 24, 2023
Gastric Adenocarcinoma Trial (cadonilimab combined +paclitaxel (albumin-bound))
Not yet recruiting
- Gastric Adenocarcinoma
- cadonilimab combined +paclitaxel (albumin-bound)
- (no location specified)
Nov 1, 2023
Lung Adenocarcinoma, Frozen Section, Sublobar Resection Trial in Shanghai (Sublobar Resection)
Recruiting
- Lung Adenocarcinoma
- +2 more
- Sublobar Resection
-
Shanghai, Shanghai, ChinaFudan University Cancer Center
Sep 4, 2023
HER-2 Expression in Pancreatic Duct Adenocarcinoma
Completed
- Pancreatic Adenocarcinoma
- immunohistochemical approach
- (no location specified)
Sep 20, 2023
Tumor Microenvironment
Active, not recruiting
- Lung Adenocarcinoma
- (no location specified)
Aug 5, 2023
Colorectal Adenocarcinoma Trial in Padova (Impact Oral®)
Not yet recruiting
- Colorectal Adenocarcinoma
- Impact Oral®
-
Padova, ItalyIstituto Oncologico Veneto IRCCS
Nov 10, 2023
Esophagogastric Adenocarcinoma Trial (Sacituzumab govitecan)
Not yet recruiting
- Esophagogastric Adenocarcinoma
- Sacituzumab govitecan
- (no location specified)
Nov 9, 2023
Adenocarcinoma Esophagus, Locally Advanced Adenocarcinoma, Siewert Type I Adenocarcinoma of Esophagogastric Junction Trial
Not yet recruiting
- Adenocarcinoma Esophagus
- +3 more
- Vactosertib
- +2 more
- (no location specified)
Sep 13, 2023
Lung Adenocarcinoma Trial in Shijiazhuang (Tislelizumab,Platinum)
Recruiting
- Lung Adenocarcinoma
-
Shijiazhuang, Hebei, ChinaThe Fourth Hospital of Hebei Medical University (Hebei Tumor Hos
Sep 24, 2023
IA Lung Adenocarcinoma, Combined Segmentectomy Trial in Fuzhou (Patients receive subsegmentectomy)
Active, not recruiting
- IA Lung Adenocarcinoma
- Combined Segmentectomy
- Patients receive subsegmentectomy
-
Fuzhou, ChinaFujian Medical University Union Hospital
Aug 2, 2023
Gastroesophageal Adenocarcinoma Trial (Paclitaxel, Ramucirumab, Zanidatamab)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- Paclitaxel
- +2 more
- (no location specified)
Sep 12, 2023
Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)
Not yet recruiting
- Adenocarcinoma - GEJ
- Gastric Adenocarcinoma
- (no location specified)
Sep 26, 2023
Pancreatic Ductal Adenocarcinoma, Oligometastatic Disease Trial in Baltimore (FOLFIRINOX chemo)
Not yet recruiting
- Pancreatic Ductal Adenocarcinoma
- Oligometastatic Disease
- FOLFIRINOX chemotherapy
-
Baltimore, MarylandJohns Hopkins Hospital
Nov 2, 2023
Invasiveness for Small-sized Lung Adenocarcinoma
Recruiting
- Lung Adenocarcinoma, Stage I
- Invasiveness diagnosis
-
Wuhan, Hubei, ChinaUnion Hospital, Tongji Medical College, Huazhong University of S
Apr 13, 2023
Ethmoid Sinus Tumor, Adenocarcinoma, Circulating Tumor Cell Trial (Liquid biopsy)
Not yet recruiting
- Ethmoid Sinus Tumor
- +2 more
- Liquid biopsy
- (no location specified)
Oct 18, 2023
Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, PDAC Trial in Boston (other, diagnostic test, combination product)
Not yet recruiting
- Pancreatic Cancer
- +4 more
- Screening Blood Tests
- +3 more
-
Boston, Massachusetts
- +1 more
Nov 3, 2023
Pancreas Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma, Locally Advanced Pancreatic Adenocarcinoma Trial in
Not yet recruiting
- Pancreas Adenocarcinoma
- +2 more
- Nab paclitaxel
- +3 more
-
Winston-Salem, North CarolinaWake Forest Baptist Comprehensive Cancer Center
Apr 19, 2023
Pancreas Cancer, Pancreas Adenocarcinoma Trial in Cleveland (Capecitabine)
Not yet recruiting
- Pancreas Cancer
- Pancreas Adenocarcinoma
-
Cleveland, OhioUniversity Hospitals Cleveland Medical Center, Seidman Cancer Ce
Oct 29, 2023
Gastroesophageal Junction Adenocarcinoma Trial in Beijing (Serplulimab)
Recruiting
- Gastroesophageal Junction Adenocarcinoma
-
Beijing, ChinaPeking Union Medical College Hospital
Jun 15, 2023
Pabolizumab for Neoadjuvant Immunotherapy of Locally Advanced
Recruiting
- Gastric Cancer
- Gastric Adenocarcinoma
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Apr 4, 2023
Bile Duct Adenocarcinoma Trial in Hangzhou (surufatinib plus cadonilimab)
Recruiting
- Bile Duct Adenocarcinoma
- surufatinib plus cadonilimab
-
Hangzhou, Zhejiang, ChinaZhejiang Cancer Hospital
Oct 15, 2023
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma = 2cm
Recruiting
- Lung Adenocarcinoma
- Lobectomy with systemic lymph node dissection
- Segmentectomy with systemic lymph node dissection
-
Yangpu, Shanghai, ChinaShanghai Pulmonary Hospital
Apr 20, 2023
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma Trial (Cadonilimab, AK117, Oxaliplatin)
Not yet recruiting
- Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
- Cadonilimab
- +5 more
- (no location specified)
Jul 17, 2023
Tumor Size and Prognosis in Small Bowel adenocarcinoma-a
Completed
- Prognosis
- no interventions
-
Dalian, Liaoning, ChinaDalian Third People's Hospital Affiliated to Dalian Medical Univ
Oct 11, 2023